On August 30, 2024, the results of the first-in-human Phase Ia dose-escalation study of Escugen's core product ESG401 were officially published online in the renowned international medical journal Cell Reports Medicine (impact factor: 11.7), a subjournal of Cell. The study was jointly led by the Cancer Hospital of the Chinese Academy of Medical Sciences and the Second Affiliated Hospital of Zhejiang University School of Medicine. Professors Ma Fei and Qiu Fuming served as the co-corresponding authors, while Dr. Wang Jian and Professor Tong Zhongsheng were the co-first authors. The publication of these results in Cell Reports Medicine highlights the international academic community's high recognition of the innovative development and clinical research outcomes of ESG401.
